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Tumor cells, including cancer stem cells (CSCs) resistant to radio- and chemotherapy,
must enhance metabolism to meet the extra energy demands to repair and survive such
genotoxic conditions. However, such stress-induced adaptive metabolic alterations,
especially in cancer cells that survive radiotherapy, remain unresolved. In this study,
we found that CPT1 (Carnitine palmitoyl transferase I) and CPT2 (Carnitine palmitoyl
transferase II), a pair of rate-limiting enzymes for mitochondrial fatty acid transportation,
play a critical role in increasing fatty acid oxidation (FAO) required for the cellular fuel
demands in radioresistant breast cancer cells (RBCs) and radiation-derived breast
cancer stem cells (RD-BCSCs). Enhanced CPT1A/CPT2 expression was detected in
the recurrent human breast cancers and associated with a worse prognosis in breast
cancer patients. Blocking FAO via a FAO inhibitor or by CRISPR-mediated CPT1A/CPT2
gene deficiency inhibited radiation-induced ERK activation and aggressive growth and
radioresistance of RBCs and RD-BCSCs. These results revealed that switching to FAO
contributes to radiation-induced mitochondrial energy metabolism, and CPT1A/CPT2 is
a potential metabolic target in cancer radiotherapy.
Keywords: breast cancer stem cells, CPT1A/CPT2, FAO, metabolism, radioresistance, breast cancer
INTRODUCTION
Radiation therapy (RT) is the major modality in treatment of solid cancer, including breast cancer
(BC), with reported clinical benefits (1, 2). A meta-analysis of 10,801 women with or without RT
after breast-conserving surgery in randomized trials demonstrated that RT reduced the 10-year
risk of any first recurrence (locoregional or distant tumors) from 35.0 to 19.3% and reduced the
15-year risk of BC mortality rate from 25.2 to 21.4% (1). Cancer stem cells (CSCs; also termed as
tumor-initiating cells, TICs) are suggested to be the carcinogenic cell source and responsible for
tumor aggressive phenotype and failure of anti-tumor therapy (3, 4). To further improve the BC
long-term efficacy by RT, the mechanisms linked with the adaptive radioresistance and recurrent
risk in CSCs are to be investigated (5–8).
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Elucidation of the metabolic dynamics of resistant breast
cancer cells (RBCs) will help to identify metabolic targets to
synergize the efficacy of RT. The theory of aerobic glycolysis
in malignant cells (Warburg Effect) (9–11) is being updated,
with emerging new evidence indicating an adaptive energy
reprogramming in tumor cells with mitochondrial reactivation
and oxidative phosphorylation (12, 13). We have reported that
mitochondrial MnSOD activity is required for radioresistance
in BC cells (14, 15) and radiation can enhance mitochondrial
OXPHOS in tumor cells (16). Enhanced mitochondrial
bioenergetics are found to be the major cellular fuel supplement
for cell cycle progression (17–19), tumor aggressive phenotype
and metastasis (20). Accumulating new evidence indicates that
reprogramming inmitochondrial metabolism is actively involved
in tumor proliferation and metastasis (12, 21–23). Mitochondrial
energy output is also required for nuclear DNA repair after
IR (24), and mitochondrial FAO is linked with BC metastasis
(25, 26). With such a flexible adaptive energy metabolism
detected in the malignant cells (13, 27), it is reasonable to
look into the deep mechanistic insights of reprogramming
mitochondrial bioenergetics in aggressive tumors, especially
the RBCs.
Under genotoxic stress conditions, such as chemotherapy or
radiotherapy, tumor cells must acquire additional cellular fuel
resource to meet the increased demands of energy consumption
for damage repair and survive (24). In addition to glucose, fatty
acids with high ATP yield are a relevant energy-rich source
in cancer cells under such genotoxic crisis. The FAO-mediated
mitochondrial bioenergetics has been assumed to play a critical
role in cell proliferation, cancer stemness and chemoresistance
(28–30). Inhibition of mitochondrial FAO by etomoxir impairs
NADPHproduction and increases reactive oxygen species (ROS),
resulting in ATP depletion and cell death in human glioblastoma
cells (31). In mitochondrial FAO pathways, targeting CPT1A
generates clinic benefits in RT for nasopharyngeal carcinoma
patients (32). However, the precise network of FAO enhancement
in reprogramming mitochondrial energy metabolism, especially
in resistant breast cancer cells, remains to be elucidated.
To mimic clinical radioresistance, in this study, RBCs were
generated from wild type breast cancer cells via continuous
ironizing radiation (IR), and the radioresistant BCSCs cells
were sorted from the RBCs (8), termed as radiation-derived
BCSCs (RD-BCSCs). Using proteomics of RD-BCSCs and
CRISPR-mediated FAO gene editing, here we revealed a novel
mitochondrial lipid metabolic reprogramming in RBCs and
RD-BCSCs. The mitochondrial fatty acid oxidation (FAO)
was enhanced in both RBCs and RD-BCSCs and linked
with recurrent BC and a worse prognosis in BC patients.
Blocking FAO by CRISPR-mediated CPT1A/CPT2 KO inhibited
aggressive phenotype of the radioresistant BC with down-
regulation of the ERK pathway, indicating a potential metabolic
target in breast cancer radiotherapy.
MATERIALS AND METHODS
RBCs, RD-BCSCs, and Other Reagents
MCF7 and MDA-MB-231 human breast cancer cells were
purchased from ATCC (Manassas, VA, USA). MCF7/C6
radioresistant clone is a single clone surviving from MCF7/WT
cells after fractionated ionizing radiation treatment (2Gy ×
15) (33, 34). MDA-MB-231/C4 are radioresistant breast cancer
cells surviving from MDA-MB-231/WT cells after fractionated
radiation (2Gy × 30) (35). MCF7, MCF7/C6, MDA-MB-
231, and MDA-MB-231/C4 cells were cultured in DMEM
medium with 10% fetal bovine serum (FBS, Life Technologies,
NY, USA) and 1% penicillin/streptomycin (Life Technologies).
RD-BCSCs were sorted as previously described (8, 36). Cell
pellets of MCF7/C6 were rinsed with cold PBS with 2%
FBS and then suspended with PBS containing 0.5% FBS and
0.5 mg/mL PI (Sigma, St. Louis, MO, USA). Then, the cell
suspension was sorted using Cytopeia influx Cell Sorter (BD
Biosciences, San Jose, CA, USA). The antibody against HER2/neu
was conjugated to allophycocyanin (APC, BD Biosciences,
San Jose, CA), anti-human CD44 was conjugated to FITC,
and human CD24 was conjugated to phycoerythrin (PE;
Invitrogen, Carlsbad, CA). Cell viability was assessed by 7-AA
staining during cell sorting and then determined by trypan
blue exclusion after sorting (Figure S1A). The isolated RD-
BCSCs (CD44+/CD24−/low/HER2+) were maintained in CSC
medium containing free serum and supplemented with B27
(Life Technology, Carlsbad, CA, USA), 20 ng/ml EGF (Biovision,
Mountain View, CA, USA), 20 ng/ml basic-FGF, and 4µg/ml
heparin (VWR, Philadelphia, PA, USA). Cells were cultured in
ultralow-attachment Petri dishes with 5% CO2 at 37◦C. All cell
lines were tested mycoplasma free before experiments. Etomoxir
was purchased from Sigma-Aldrich. Oil RedOwas obtained from
Millipore Sigma (St. Louis, MO, USA).
Western Blot
Western blot was performed as previously described (37). Briefly,
the cell lysates were separated on SDS-PAGE gels and transferred
to PVDF membranes. The membranes were blocked with 5%
milk for 1 h, and then incubated with primary antibodies with
shaking at 4◦C overnight. In the next day, the membranes were
incubated with horseradish peroxidase-conjugated secondary
antibodies for 1 h at room temperature. The protein blots
were developed using an enhanced chemiluminescence western
blot detection system (BioRad, Hercules, CA, USA). Antibodies
against HER2/Neu (C-18, #SC284), CPT2 (G-5, #SC-377294),
HADHA (E-8, #SC374497), HADHB (E-1, #SC-271495), ERK1/2
(C-9, #SC514302), and c-Fos (E-8, SC#166940) were all diluted
at 1:500 and purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Anti-CPT1A (clone D3B3, #12252), Phospho-
p44/42 MAPK (Thr202/Tyr204, clone 197G2, #4377), Phospho-
GSK3 β (Ser9, #9336), GSK3 β (clone 27C10, #9315), Phospho-
STAT3 (Ser727, clone D8C2Z, #94994), and Phospho-JNK
(Thr183/Tyr185, #9251) were from Cell Signaling Technology
(Beverly, MA, USA). Antibody against ACAD9 (#3170340688)
was purchased from Novus Biologicals (Littleton, CO, USA).
Anti-β-actin at 1:2000 (#A2066) was from Sigma-Aldrich.
Fatty Acid Oxidation (FAO) Assay
FAO measurement was following the manufacturer’s instruction
of Fatty Acid Oxidation Assay Kits from Abcam (ab217602).
Briefly, 3×104 cells were seeded per well in 96-well plates and
cultured overnight. Then the cells were rinsed twice with 100
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µl prewarmed FA-Free medium followed by adding 90 µL pre-
warmed FA Measurement Medium. The wells without cells were
used as signal control. A total of 85 µL of FA-Free Measurement
medium was added to the wells, and 5 µL of BSA control
were included as the FA-free control. All wells except the blank
control had 10µL Extracellular O2 Consumption Reagent added.
The FAO activator FCCP (0.625µM) and inhibitor Etomoxir
(40µM) were added as the positive and negative controls. Then
the wells were sealed with 100 µL pre-warmed mineral oil,
and the FAO was measured using the condition as Extracellular
Oxygen Consumption. The results were normalized by the
protein concentration with the cells in each sample under the
BCA assay.
Lipid Accumulation Assay
Breast cancer cells were plated and cultured in 96-well plates. In
the next day, cells were treated with 250µM free fatty acid (oleic
acid: palmitate acid= 2:1) for 48 h. After being washed with PBS
twice, cells were fixed with 4% paraformaldehyde under room
temperature (RT) for 30min. Cells were washed with sterilized
water once and added into 50 µL Oil Red working solution;
they were then incubated for 15min at RT. Then 50 µL 60%
isopropanol was added to the cells for 20 s at RT. Finally, the
cells were washed with water twice, and the images were obtained
using a Nikon microscope (Eclipse, E1000M, Japan). The red oil
dye was eluted with 50 µL DMSO and incubated for 10min with
gentle shaking. The lipid accumulation results were determined
by the fluorescence microplate spectrophotometer (Molecular
Devices) at 510 nm.
Oxygen Consumption
Extracellular Oxygen Consumption detection was performed
following the instruction of kit from Abcam (ab197243,) with
3 × 104 cells seeded per well in 96-well plates and cultured at
37◦C overnight. The cell medium was replaced with 150 µl fresh
culture media followed by adding 10 µl of extracellular oxygen
consumption reagent. The wells without oxygen consumption
reagent were used as blank control. Wells with Etomoxir
(40µM) added were included as the negative control. Wells
had 100 µl of pre-warmed mineral oil added to avoid the air
bubbles. The plates were read immediately in a fluorescence
microplate spectrophotometer (Molecular Devices) at 37◦C. The
signals were collected at 1.5min intervals for 90–120min at
Ex/Em = 380/650 nm. The results were normalized by protein
concentration of the cells in each sample under the BCA assay.
MTT Assay
Breast cancer cells were seeded in 96-well plates for 24 h. After
they proliferated to about 90% confluence, the cells were added
into 50∼100 µL MTT solution (M-2128, Sigma) and cultured
at 37◦C for 2 h. The results were measured in a microplate
spectrophotometer (Molecular Devices) at 540 nm.
Cell Apoptosis Assay
Breast cancer cells were rinsed by cold PBS twice, collected
and stained using the Annexin-V/PI kit (Biosource, Invitrogen,
Carlsbad, CA, USA) according to manufacturer’s protocol.
Stained cells were analyzed by flow cytometry (Becton Dickinson
canto II, BD, NJ, USA). Data were analyzed using Flowjo software
(Three Star, Inc., Ashland, OR, USA).
Colony Formation Assay
For measuring cellular clonogenicity, 1 × 103 cells were seeded
into 6-well plates and treated with or without 5Gy radiation
in the next day. Cells were then cultured for 14 days at 37◦C.
The colonies were fixed and stained with Coomassie blue, and
then colony formation rate was determined by counting colonies
in each group. Finally, the colony images were observed and
recorded by a Nikon microscope (Eclipse, E1000M, Japan) (8).
Immunohistochemical Staining (IHC)
The slides of primary biopsy tissues and recurrent tumors from
patients with breast cancer were tested by immunohistochemistry
(IHC) using Vectastain ABC kit and DAB Peroxidase Substrate
kit SK-4100 (Vector Laboratories, Burlingame, CA, USA). The
prepared tumor slides were firstly deparaffinized, hydrated, and
then covered with blocking buffer for 1 h after heat-induced
epitope retrieval. The slides were incubated with anti-CPT1A
(Cell Signaling Technology, #12252) and anti-CPT2 (Santa Cruz,
sc-20671) at 1:200 at 4◦C overnight, followed by washing with
PBST three times, and then incubated with the secondary
antibody for 30min at RT. The slides were then covered with
ABC solution for 30min on the shaker at RT. The slides were
incubated with DAB solution about 2min and then transferred
to hematoxylin, HCl solution and Li2CO3 solution quickly
several times. Finally, the slides were dehydrated and sealed.
The slides were observed and recorded by Nikon microscope
(Eclipse, E1000M).
CRISPR-Mediated Gene Editing
The single guide RNA (sgRNA) was designed according the
CRISPR Design in Zhang Lab https://zlab.bio/guide-design-
resources. We created oligonucleotide to target genes CPT1A
and CPT2. The sgRNA sequences are designed as follows:
human CPT1A: CTCCGGACGGGATTGACCTG; human
CPT2: CGGGGCCCCGCGGTTGGTCC. The LentiCRISPRv2
backbone was used, which contains the hSpCas9 and sgRNA
expression cassettes. Plasmids were purchased from the
Addgene plasmid repository (Addgene #52961) (https://www.
addgene.org/). Backbone LentiCRISPRv2 was annealed to
oligonucleotides following the Zhang Lab GeCKO protocol
and packaged into lentiviruses. The Lentiviral particles were
produced inHEK293T cells following the protocol fromAddgene
(38), and breast cancer cells were infected with lentiviruses and
selected with 0.3µg/ml puromycin. Western blot analysis was
performed to identify cell colonies with gene deficiency.
Proteomics of RD-BCSCs and MCF7 Cells
The protein mixture from total cell lysates of RD-BCSCs and
MCF7 was first treated with dithiothreitol and iodoacetamide
for cysteine reduction and alkylation, respectively. The protein
samples were then digested using modified sequencing-grade
trypsin (Roche, Basel, Switzerland) at an enzyme/substrate ratio
of 1:100 in 50mM NH4HCO3 (pH 8.5) at 37◦C overnight.
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The peptide mixture was subsequently dried in a Speed-vacuum
and desalted by employing OMIX C18 pipet tips (Agilent
Technologies, Santa Clara, CA, USA), reconstituted in water
and subjected to LC-MS and MS/MS analyses on a Q Exactive
Plus mass spectrometer equipped with a nanoelectrospray
ionization source. Samples were automatically loaded from a 48-
well microplate autosampler using an EASY-nLC 1200 system
(Thermo Fisher Scientific, Rockford, IL, USA) at 3 µL/min
onto a biphasic precolumn (150µm i.d.) comprised of a 3.5-cm
column packed with 5µm C18 120 Å reversed-phase material
(ReproSil-Pur 120 C18-AQ, Dr. Maisch). The biphasic trapping
column was connected to a 20-cm fused-silica analytical column
(PicoTip Emitter, New Objective, 75µm i.d.) with 3µm C18
beads (ReproSil-Pur 120 C18-AQ, Dr. Maisch). The peptides
were then separated using a 180-min linear gradient of 2–45%
acetonitrile in 0.1% formic acid and at a flow rate on 250 nL/min.
The mass spectrometer was operated in a data-dependent scan
mode. Full-scan mass spectra were acquired in the range of
m/z 350–1,500 using the Orbitrap analyzer with a resolution
of 70,000. Up to 25 of most abundant ions found in MS with
a charge state of 2 or above were sequentially isolated and
collisionally activated in the HCD cell with collision energy of 27
to yield MS/MS.
Bioinformatics Analysis
Maxquant (Version 1.5.2.8) was used to analyze the LC-MS and
MS/MS data for the identification and quantification of proteins
in the LFQ mode (39). The maximum number of mis-cleavages
for trypsin was two per peptide. Cysteine carbamidomethylation
was set as a fixed modification. Methionine oxidation and
phosphorylation on serine, threonine, and tyrosine were set as
variable modifications. The tolerances in mass accuracy for MS
and MS/MS were both 20 ppm. Maximum false discovery rates
(FDRs) were set to 0.01 at both peptide and protein levels,
and minimum required peptide length was six amino acids.
The LC-MS and MS/MS protein data were also analyzed with
functional clustering. Of all proteins in our total protein array,
only proteins that showed levels of detection were submitted
to DAVID Bioinformatics Resources v6.7 (https://david.ncifcrf.
gov/). Parameters were established for our functions of interest
with a cutoff of p < 0.05.
Category Selection of Proteomics
DAVID Bioinformatics Resources provide a wealth of
information within the Gene Ontology Tool for Biological
Function (40, 41). Different broad categories were generated to
profile the cluster of proteins related to varied cellular functions
including mitochondrial bioenergetics and lipid metabolism
as well as FAO. We used the Uniprotein tagging system,
UPKeyword due to the high number of hits in the protein list.
Tumorsphere Formation
Tumorsphere assay was performed as described (42). Cells were
sieved with 40µm cell strainers (Fisher, Failawn, NJ, USA) and
single-cell suspensions were seeded into 60mm Petri dishes.
The cells were grown in serum-free mammary epithelial basal
medium (MEBM, Lonza,Walkersville, MD, USA), supplemented
with B27, 20 ng/ml EGF, 20 ng/ml basic-FGF, and 4µg/ml
heparin. Cells were then cultured for 10 days, and tumor spheres
were counted under light microscopy.
Three-Dimensional (3D) Morphogenesis
Assay
MCF7 and RD-BCSC cells in 40 µL plug of Matrigel (growth
factor reduced and phenol red free, Becton Dickinson, Plymouth,
UK) were plated to the well of an 8-well LabTek Chambered
coverglass (Nunc, Rochester, USA) at 37◦C for 30min. On ice,
cells were prepared at a concentration of 5,000 cells/ml in KSFM
supplementedwith 5 ng/ml EGF, 2% (v/v) FCS, 4% (v/v)Matrigel,
and 0.2mL of this cell solution was plated onto the Matrigel
plug and incubated for 30min at 37◦C, after which 0.2mL of
growth medium was added (KSFM supplemented with 5 ng/mL
EGF, 2% (v/v) FCS). Culture medium was changed every 2–3
days. At day 10, morphology was assessed by phase microscopy
and cells were fixed and processed for immunofluorescence
microscopy analysis.
Statistical Analysis
Statistical significance of differences was evaluated using two-
tailed student t-test for two groups’ comparison or one-way
ANOVA test where multiple groups were involved. p < 0.05 was
considered statistically significant.
RESULTS
Mitochondrial FAO Is Enhanced in
Radioresistant Breast Cancer Cells
Lipid metabolism has been linked with cancer therapy
response (28–30). Here we address the question of whether
reprogramming mitochondrial FAO plays a key role in breast
cancer radioresistance. Two radioresistant BC (RBC) cell lines
(MCF7/C6 and MDA-MB-231/C4) isolated from surviving
MCF7 and MDA-MB-231 residues with HER2 induction and
aggressive phenotype after chronical radiation (Figure S1A)
(8, 35) showed enhanced expressions of mitochondrial FAO
genes CPT1A, CPT2, HADHB, and ACAD9 (Figure 1A). We
then measured the mitochondrial FAO activity by 18C-labeled
unsaturated fatty acid oleate as the substrates with CPT1A
specific inhibitor Etomoxir (ETX) and the FAO activator FCCP
as negative and positive controls, respectively, demonstrating a
significant elevation of FAO activity in MCF7/C6 vs. wild type
MCF7 cells (Figure 1B). Furthermore, enhanced lipid turnover
rate was detected in MCF7/C6 cells loaded with free fatty acid
(FFA), which was contrasted with the markedly accumulation
of FFA in the wild type MCF7 cells (Figure 1C), indicating
enhanced FAO metabolism in RBC cells.
We next determined whether the FAO is enhanced in
the human recurrent breast tumors compared to the primary
tumors. CPT1 and CPT2 are the rate-limiting transporters
and play a key role in mitochondrial long-chain FAO and
lipid metabolism. Remarkably, the enhanced co-expression of
CPT1A (an isoform of CPT1) and CPT2 was mostly detected
in the pathological sections of recurrent BC tumors compared
to the paired original biopsy specimens in a group of 12 BC
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FIGURE 1 | FAO is enhanced in radioresistant BC cells and recurrent BC and linked with a poor prognosis in BC patients. (A) Western blot of a cluster of FAO
enzymes and HER2 in wild type MCF7, MDA-MB-231, and their counterpart radioresistant MCF7/C6 and MDA-MB-231/C4 cells. (B) FAO activity assay of MCF7
and MCF7/C6 cells with MCF7/C6 treated with FAO inhibitor Etomoxir (40µM) as a negative control and FAO enhancer FCCP (1µM) as a positive control. (C) Fatty
acid turnover rate in MCF7 and MCF7/C6 cells treated with or without 250µM Free Fatty Acid (FFA; oleic acid: palmitic acid = 2:1) for 24 h before Oil Red staining
(Continued)
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FIGURE 1 | (left: quantitation of lipid accumulation; right: representative images of FFA accumulation). (D) Representative IHC of CPT1A and CPT2 in biopsy and
recurrent BC (left). Quantitation of IHC was achieved by scoring staining intensity and positive cells (right). (E) Elevated CPT1A/CPT2 expression correlates a worse
overall survival of BC patients in the TCGA database http://bioinformatica.mty.itesm.mx:8080/Biomatec/SurvivaX.jsp. Error bars in (B–D) represent the mean ±
standard deviation. Significance was determined by one-way ANOVA test, *p < 0.05, **p < 0.01, ***p < 0.001.
patients (Figure 1D). In agreement, the TCGA database revealed
a poor prognosis in BC patients with increased expression
of CPT1A or CPT2 (Figure 1E) (http://bioinformatica.mty.
itesm.mx:8080/Biomatec/SurvivaX.jsp). Together, these results
indicate that reprogramingmitochondrial FAO contributes to BC
radioresistance and worse prognosis.
CPT1A/CPT2 Mediated FAO Is Required for
Radioresistant Breast Cancer Stem Cells
Our previous results have indicated that mitochondrial
energy enhancement is involved in BC aggressiveness due
to HER2 expression (15, 43) that is confirmed in Figure 1A.
Following the standard biomarkers of breast cancer stem
cells (BCSCs) (4) and our established BCSCs from MCF7/C6
with HER2 induction as radiation-derived BCSCs (RD-
BCSCs; CD44+/CD24−/low/HER2+ with enhanced ALDH
activity (8), we compared the tumorspheres from RD-BCSCs
and MCF7 shown in Figure 2A. The tumorsphere of RD-
BCSCs showed severely disorganized structure with altered
distribution of cellular polarity protein (DLG, red) and enhanced
HER2 expression (green), indicating an aggressive phenotype
of RD-BCSCs.
Consistent with the results of RBC in Figure 1A, the key FAO
enzymes, CPT1A, CPT2, and HADHB, were also enhanced in
RD-BCSCs (Figure 2B), and both basal and irradiated FAO levels
were elevated in RD-BCSCs whereas no significant FAO elevation
was detected in irradiated MCF7 compared to basal level,
although the proteomics data showed enhanced mitochondrial
proteins in both irradiated both MCF7 and RD-BCSCs
(Figure 2C, Figures S2A, S3), suggesting that reprogramming
FAO is an unique feature of RD-BCSCs. This is further evidenced
by the specifically enhanced cluster of factors in lipid metabolism
rather than other cellular proteins in irradiated RD-BCSCs (47
to 81 in RD-BCSCs vs. 55 to 76 in MCF7); and the protein
intensity was also more increased in irradiated RD-BCSCs (5.24-
fold) contrasted to 2.31-fold in MCF7 (Figures S1B,C). The
FAO inhibitor Etomoxir (ETX) significantly enhanced basal
and radiation-induced apoptosis with inhibited tumorsphere
formation and ERK activity in RD-BCSCs (Figures 2D–F,
Figure S2B). In agreement, blocking CPT1A/CPT2 by CRISPR-
mediated gene deficiency (Figure 2G), enhanced apoptosis level
and reduced the tumorsphere formation in RD-BCSCs upon
IR (Figures 2H,I, Figure S2C). Additional proteomics evidence
suggested that mitochondrial proteins were more enriched in
the RD-BCSCs compared to MCF7 cells after radiation. The
total mitochondrial protein counts increased from the same basal
117 in MCF7 and RD-BCSCs to 152 and 163, 29.9, and 39.3%
respectively, whereas protein intensity had a 2.64-fold increase
(4.50E+10 to 1.06E+11) in RD-BCSCs compared to a 1.83-
fold increase in MCF7 cells (Figures S3A,B). Additionally, we
further analyzed the mitochondrial proteins and found that FAO
metabolism was also demonstrated with an increased protein
number, from 11 to 17, in irradiated RD-BCSCs including
CPT1A and CPT2 (Figures S4A,B, Table S1), indicating that
enhanced mitochondrial FAO contributes to radioresistance
of RD-BCSCs.
ERK Activation Is Linked With
Mitochondrial FAO Enhancement
To explore the key factors responsible for FAO-mediated
radioresistance, we tested an array of cell proliferating factors
in the two RBC cell lines by CRISPR-mediated knockout of
CPT1A and CPT2 (Figure 3A). Strikingly, the activated form of
ERK1/2 was absent in the CPT1A and CPT2 KO cells, although
other cell growth factors including phosphor-GSK3β, phospho-
STAT3, and phospho-JNK were also reduced to a certain
degree (Figure 3B). Alternatively, a dose-dependent inhibition of
phospho-ERK and its downstream effectors was also determined
in MCF7/C6 cells with increasing concentrations of ETX
(Figure 3C). It turned out that 200µm ETX could dramatically
block the phosphorylation of ERK1/2. The dependence of
ERK1/2 kinase in the FAO-mediated resistance was again
evaluated by a rescue experiment, in which the FAO activity
was inhibited by ETX and then activated by L-carnitine. As
expected, the induction of phospho-ERK1/2 upon radiation
was significantly inhibited by etomoxir while enhanced by
L-carnitine. Of note, the combination of etomoxir and L-
carnitine treatment ablated the phospho-ERK1/2 induction by
L-carnitine treatment upon radiation (Figures 3D,E). Together,
our inhibition and rescue experiments consistently demonstrated
that FAO mediated radioresistance is linked with ERK1/2
activation for the aggressive phenotype of radioresistant breast
cancer cells.
Deficiency of CPT1A or CPT2 Reduces
OCR, Cell Viability, and Slowdown Fatty
Acid Turnover Rate in RBC Cells
By comparing the metabolic features of BC cells and RBCs,
we found that both the oxygen consumption rate and cell
viability were enhanced in MCF7/C6 cells compared to MCF7
cells, but remarkedly reduced by ETX or in CPT1A/CPT2 KO
(Figures 4A,B). Additionally, ETX treatment and CPT1A/CPT2
KO increased FFA accumulation, indicating a slower fatty
acid turnover (Figure 4C). The colony formation assay was
used to evaluate the cell survival rates when given radiation
therapy with FAO inhibition in RBCs. The colonies in the
RBCMCF7/C6 and MDA-MB-231/C4 cells were more abundant
than the basal clonogenic capacity of the parental MCF7
and MDA-MB-231 cells, indicating an enhanced aggressive
phenotype of RBCs. However, the etomoxir treatment and
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FIGURE 2 | CPT1A/CPT2 mediated FAO is required for radioresistant breast cancer stem cells. (A) Representative mammospheres formed from MCF7 and
RD-BCSCs assessed by immunofluorescence microscopy (cell polarity protein DLG1, HER2, and nucleus are labeled by red, green, and blue respectively).
(B) Western blot of FAO enzymes CPT1A, CPT2, and HADHB in MCF7 and RD-BCSCs cells. (C) FAO activity in MCF7 and RD-BCSCs with or without IR treatment
for 24 h. (D) Radiation-induced apoptosis measured in RD-BCSCs with or without FAO inhibition (ETX, Etomoxir 200µM for 48 h). (E) Tumorsphere formation assay
of (D). (F) Western blot of phosphorylated ERK in RD-BCSCs treated with ETX, IR or combined. (G) Western blot of CPT1A and CPT2 in RD-BCSCs with
CRISPR-mediated CPT1A and CPT2 KO. (H) Radiation induced apoptosis in RD-BCSCs (Control), RD-BCSCs CPT1A KO, and RD-BCSCs CPT2 KO cells.
(I) Tumorsphere formation of (H). In (C,D,E,H,I) n = 3; mean ± SD; one-way ANOVA test, *p < 0.05, ***p < 0.001.
CPT1A/CPT2 KO markedly reduced the survival colony rate
in MCF7/C6 and MDA-MB-231/C4 cells (Figures 5A–D). IR
induced cellular apoptosis was also evaluated in the RBCs.
The FAO inhibition increased radiation-induced apoptosis
from 10 to 34% (etomoxir treatment), 31% (CPT1A KO),
and 36% (CPT2 KO) in MCF7/C6 cells and from 3.8 to
5% (etomoxir treatment), 9.2% (CPT1A KO), and 7.7%
(CPT2 KO) in MDA-MB-231/C4 cells (Figures 6A,B). FAO
inhibition also reduced tumorsphere formation from 58 to
34.5 (etomoxir treatment), 26.5 (CPT1A KO), and 24.5
(CPT2 KO) with IR in MDA-MB-231/C4 cells (Figure 6C).
Together, these results indicate that CPT1A/CPT2 mediated
FAO enhancement is required for the energy demands and cell
survival in RBCs. In summary (Figure 7), our results reveal that
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FIGURE 3 | ERK proliferative pathway is linked with FAO enhancement. (A) Western blot of CPT1A and CPT2 in control and MCF7/C6 and MDA-MB-231/C4 cells
with CRISPR KO CPT1A and CPT2. (B) Western blot of proliferative genes in irradiated MCF7, MCF7/C6, MCF7/C6 CPT1A KO, and MCF7/C6 CPT2 KO cells.
(C) Western blot of MCF7/C6 cells treated with increased doses of ETX for 24 h followed by 5Gy IR. (D) Western blot of pERK in MCF7/C6 cells treated with ETX,
L-carnitine (an FAO enhancer) or combined followed by 5Gy IR. (E) Western blot of pERK in MDA-MB-231 cells were treated ETX, L-carnitine (an FAO enhancer) or
combined followed by 5Gy IR.
reprogramming mitochondrial FAO is the major cellular energy
supplement in radioresistant breast cancer cells. Such adaptive
mitochondrial energy metabolism is linked with the clinical
outcome of BC patients treated with radiotherapy. We also
reveal that the ERK-mediated prosurvival pathway is a potential
downstream target in FAO-mediated aggressive proliferation in
BC with enhanced activation of HER2 leading to promoted
cell proliferation.
DISCUSSION
It is highly clinically relevant to reveal the major cellular
energy driving the growth of therapy-resistant cancer cells. The
concept of aerobic glycolysis in cancer metabolism (Warburg
Effect), believing the deficient mitochondrial function in cancer
cells, has been updated with accumulating results of active
tumor metabolic to oncogenic (9) and genotoxic stress including
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FIGURE 4 | Blocking CPT1A/CPT2 inhibits FAO and fatty acid turnover in RBC cells. (A) Basal oxygen consumption rate (OCR) measured in MCF7, MCF7/C6, and
MCF7/C6 CPT1A KO and MCF7/C6 CPT2 KO cells with MCF7/C6 cells treated with 40µM Etomoxir for 48 h as the FAO blockade control. (B) Cell viability measured
by MTT of (A). (C) Fatty acid turnover rate in MCF7/C6, MCF7/C6 CPT1A KO, and MCF7/C6 CPT2 KO cells with MCF7/C6 treated with 40µM ETX for 48 h as FAO
inhibition control; cells were incubated with 250µM FFA (oleic acid: palmitic acid = 2:1) for an additional 24 h and then Oil Red staining; representative FA turnover
rates were shown on the right. In (A–C), n = 3; mean ± SD; significance was determined by one-way ANOVA test, *p < 0.05, **p < 0.01, ***p < 0.001.
ionizing radiation (16, 44, 45). A dynamic metabolic feature is
linked to the adaptive reprogramming in energy supply, which
is required to meet the increased cellular fuel demands for
cancer cells to repair the damage and survive anti-cancer therapy.
Identification of the metabolic targets required for tumor cell
survival under genotoxic stress conditions such as chemo-
radiotherapy are necessary for improving the therapeutic efficacy.
Among other hallmarks of cancer cell progression, cancer cells
can adjust energy metabolism to meet the demands of cellular
fuel consumption for proliferation and survival to therapeutic
stress conditions (11). In this study, we revealed a unique
metabolic feature in RBCs and radioresistant breast cancer
stem cells (RD-BCSCs). It showed that FAO enzyme expression
and mitochondrial FAO activity were enhanced in response to
radiation compared to wild type breast cancer cells. Elevated
mitochondrial FAO is required for cell growth and survival in
response of radiation therapy. Of note, CPT1A/CPT2 expression
was also elevated in human recurrent breast cancer tissues
compared to biopsy tumors. CRISPR/Cas9 mediated deficiency
of CPT1A/CPT2 efficiently enhanced sensitivity of RBCs and
RD-BCSCs to radiation treatment. Finally, we provided evidence
that mitochondrial FAO likely functions through the ERK
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FIGURE 5 | Blocking CPT1A/CPT2 synergizes radiation in eliminating clonogenic RBCs cells. Representative images (A) of colonies generated with 1 × 103 MCF7,
MCF7/C6, MCF7/C6 CPT1A KO, and MCF7/C6 CPT2 KO cells treated with or without 5Gy IR, 40µM ETX, or combined. All colonies were fixed at day 14 and
quantitated (B). (C,D) Same as (A,B) except that MDA231, MDA231/C4 CPT1A KO, MDA231/C4 CPT2 KO, and MDA231/C4 cells were tested. In all experiments,
n = 3; Error bars in (B,D) represent mean ± SD; significance was determined by one-way ANOVA test, **p < 0.01, ***p < 0.001.
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FIGURE 6 | Blocking CPT1A/CPT2 enhances apoptotic cell death and inhibits tumorsphere. (A) Representative flow cytometry of MCF7/C6, MCF7/C6 CPT1A KO,
MCF7/C6 CPT2 KO, and MCF7/C6 cells treated with 5Gy IR, ETX (40µM, 48 h), or combined (left); quantitation of apoptotic cells is shown on the right. (B) Repeated
experiments with RBC MDA-MB-231/C4 and CRISPR-KO counterparts. (C) Tumorsphere assay of (B). In (A–C), n = 3; mean ± SD; significance was determined by
one-way ANOVA test, *p < 0.05, ***p < 0.001.
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FIGURE 7 | (A) The network of enhanced FAO in radioresistant breast cancer cells due to overexpression of mitochondrial FAO and HER2. (B) Schematic pathways of
HER1/2-MEK-ERK1/2 mediated aggressive growth in radioresistant breast cancer cells due to increased mitochondrial FAO metabolism mediated by CPT1A/CPT2.
signaling pathway to confer resistance to radiation therapy
in RBCs.
Our proteomics data demonstrate a different adaptive scale of
RD-BCSCs vs. wild type MCF7 cells with a higher mitochondrial
protein number and density in RD-BCSCs than MCF7 cells.
Such differential stress response may apply to the varied response
to therapeutic radiation in primary and recurrent/metastatic
breast cancers. The plasticity of human cancer cells and the
genetic-independent acquisition of therapeutic resistance may
be tightly associated with metabolic reprogramming. CSCs
are capable of adjusting their unique metabolic plasticity in
order to respond in a timely manner and adapt to hostile
environments (46). The current study revealed that enhanced
FAO could be a critical step for therapy-resistant cancer cells,
especially cancer stem cells, to have a survival advantage, thus
they could be used for identifying and developing effective
metabolic targets. Altered metabolism is served as one of the
hallmarks of cancer and has also been observed in CSCs (47, 48).
CSCs have been identified in many types of solid tumors and
often result in recurrence and both chemo- and radioresistant
in tumors because of their self-renewal and tumorigenic
properties (49–51). It has been shown that blocking thioredoxin-
and glutathione-dependent metabolism can enhance radiation
response of BCSCs (52), indicating that in addition to FAO
enhancement, other metabolites could be critical for the survival
advantage of CSCs. Accordingly, metabolic adjustment in the
CSC populations under different therapeutic modalities should
be further investigated.
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The cellular energy shift may require a different signaling
network to drive cancer cell proliferation and radioresistance.
Our current data also reveal a potential crosstalk between
CPT1A/CPT2-mediated lipid metabolism and ERK1/2-
controlled cell proliferation (Figure 7), implicating a cooperative
network of mitochondrial FAO in response to radiation in
resistant cancer cells. Although currently there is no direct
evidence supporting mitochondrial FAO-mediated ERK1/2
activation, the enhanced mitochondrial products including ATP
from TCA cycle may increase the MEK-ERK1/2 cascade. High
ATP concentration is indicated in the tumor microenvironment
that can activate P2Y2 receptors to enhance BC cell migration
through the activation of a MEK-ERK1/2 pathway (53).
In addition, mitochondrial OXPHOS can be enhanced by
Cyclin B1/CDK1 that can be relocated into mitochondria by
radiation leading to phosphorylation of SIRT3, a key keeper
for mitochondria homeostasis at the Thr150/Ser159 (54).
Furthermore, we have recently observed that mitochondrial
homeostasis is enhanced by SIRT3-regulated CTP2 activity
in normal mouse liver cells via FAO (unpublished data).
Thus, the CPT1A/CPT2-mediated FAO activity may be
differently regulated in normal and cancer cells, which warrants
further studies.
In summary, this study reveals a previously unknown feature
of reprogramming mitochondrial FAO in RBCs due to enhanced
CPT1A/CPT2. Thus, targeting CPT1A/CPT2 as well as other
mitochondrial FAO elements may serve as a metabolic target to
enhance the efficacy of breast cancer radiotherapy.
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Figure S1 | (A) Schematic representation of the process for generating RBCs and
RD-BCSCs. (B) Functional clustering of proteomics of MCF7 and RD-BCSCs via
DAVID bioinformatics indicating the protein numbers in categories inducing lipid
metabolism, oxidation reduction, DNA repair, stress response, glycolysis, and ATP
synthesis in MCF7 cells with or without IR. The intensities of proteins in lipid
metabolism were shown in right. (C) Repeated proteomics analysis with
RD-BCSCs cells, note a group of key FAO enzymes including CPT1A and CPT2
were enhanced by radiation (marked in red in the right).
Figure S2 | (A) FAO measured in MCF7 and RD-BCSCs cells with or without 5Gy
IR treatment for 24 h. RD-BCSCs treated with 40µM Etomoxir (ETX) were used as
FAO inhibition control, and RD-BCSCs cells treated with 1µM FCCP as an FAO
enhancement control. (B) Radiation-induced apoptotic cell death measured by
Annexin-V/PI flow cytometry in RD-BCSCs cells, RD-BCSCs treated with 5Gy IR,
ETX (200µM, 48 h) or combined. (C) Repeated experiment in (B) using
RD-BCSCs CPT1A KO and RD-BCSCs CPT2 KO cells.
Figure S3 | (A) Mitochondrial fractions were prepared from MCF7 and RD-BCSCs
cells treated with or without 5Gy IR treatment and analyzed by LC-MS and
MS/MS on a Q Exactive Plus mass spectrometer. Numbers of proteins detected
comparing MCF7 and RD-BCSCs before and after IR are shown on the left.
Percentage of enhanced quantitation of the increased protein numbers by
radiation are shown in the pie on the right. (B) The intensities of mitochondrial
protein expression of MCF7 and RD-BCSCs treated with –/+ IR are shown.
Figure S4 | (A) Functional clustering of mitochondrial proteins via DAVID
bioinformatics show the relatively high enhancement of protein numbers in lipid
metabolism, oxidation reduction and ATP synthesis in the mitochondria of
irradiated RD-BCSCs. (B) The two key enzymes in mitochondrial FAO
metabolism, CPT1A, and CPT2 (in red), were enhanced by IR in RD-BCSCs.
Table S1 | The cluster of proteins involved in fatty acid metabolism enhanced by
radiation in RD-BCSCs. The mitochondrial proteomics data were generated with
mitochondrial proteins isolated from RD-BCSCs treated with or without IR,
followed by digestion with trypsin and analyses by LC-MS and MS/MS on a Q
Exactive Plus mass spectrometer. The 17 listed proteins were detected in the
proteomic analysis of mitochondrial proteins of RD-BCSCs and classified by
UniProtein under the category Lipid Metabolism. The gene symbols, descriptions,
and comparison with or without 5Gy IR are shown in the table, and the
CPT1A/CPT2 are marked with yellow.
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